More US Employers to Drop Weight-Loss Drugs
7 Articles
7 Articles
The Billings Gazette
More US employers to drop weight-loss drugs
NEW YORK — About 14% of employers in the United States have already or plan to drop GLP-1 drugs in 2027, as companies see rising healthcare costs, according to a new survey from the Business Group on Health.
More US Businesses Cut Weight-Loss Drug Coverage as Healthcare Costs Rise
U.S. employers are preparing for rising healthcare costs next year, which could lead to reduced coverage of popular GLP-1 weight-loss drugs. According to an Aug. 25 Business Group on Health’s 2027 Employer Healthcare Strategy Survey, employers are predicting a median 9.2 percent hike in healthcare costs for 2027. The report indicates that the projected cost growth could be reduced to about 8 percent through changes to employee benefit plans an…
U.S. employers are preparing for rising healthcare costs. A recent survey shows that 60% of employers will reimburse GLP-1 drugs for obesity treatment in 2026, down from 72% in 2025.
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
